Trial Profile
Phase II Trial of Perioperative PD-L1 Inhibition With Avelumab and Docetaxel, Cisplatin and 5-Fluorouracil for Resectable Locally Advanced Esophago-Gastric Adenocarcinoma
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Avelumab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Adenocarcinoma; Gastric cancer; Oesophageal cancer
- Focus Therapeutic Use
- 01 Jul 2023 Results presented at the 25th World Congress on Gastrointestinal Cancer
- 06 Jun 2023 Status changed from recruiting to active, no longer recruiting as per Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
- 06 Jun 2023 Primary endpoint has been met. (Pathologic Complete Response (pCR))